LETTER TO THE EDITOR

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study

Authors

Richard F. Schlenk,[1] Claire N. Harrison,[2] Francesca Palandri,[3] Marco De Gobbi,[4] Federico Itri,[4] Raajit Rampal,[5] Dipti Talaulikar,[6,7] Brian Jacoby,[8] Vassilios Aslanis,[8] Robert J. Slack,[8] James A. Roper,[8] Hans T. Schambye,[8] Bhupinder Singh[9] and John Mascarenhas[10]

[1]Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; [2]Guy's and St Thomas' NHS Foundation Trust, London, UK; [3]IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; [4]Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Italy; [5]Memorial Sloan Kettering, New York, NY, USA; [6]Academic Specialist Center, ACT Canberra, Australia; [7]Australian National University, Canberra, Australia; [8]Galecto Inc, Copenhagen, Denmark; [9]Galecto Inc, Kuala Lumpur, Malaysia and [10]Icahn School of Medicine at Mount Sinai, New York, NY, USA

Correspondence:
R.F. SCHLENK - Richard.schlenk@nct-heidelberg.de

https://doi.org/10.3324/haematol.2025.289108

Received: September 8, 2025.
Accepted: February 24, 2026.
Early view: March 5, 2026.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license

Supplementary Figure Legends

Figure 1	Consolidated Standards of Reporting Trials (CONSORT) flow diagram
Figure 2	Representative matrix-assisted laser desorption/ionization mass spectrometry image of A) GB2064 penetration in bone marrow for a single participant at Month 3 and B) lysyl oxidase-2 target engagement in plasma for all participants
Figure 3	Patient-reported outcomes for a) Myeloproliferative Neoplasm (MPN)10 total score - percentage change from baseline (Screening Visit). and b) EQ-5D-5L score percentage change from baseline (Screening Visit). For both graphs, values were computed on available participants with post-baseline visits (full analysis set)
Figure 4	Bone Marrow Collagen Fibrosis Changes from Baseline

Supplementary Figures

Supplementary Figure 1



Full analysis set: included all participants who received ≥1 dose of GB2064 and was the primary analysis set used for assessment of safety, tolerability and baseline population characteristics.
Pharmacokinetics population: included all participants who received ≥1 dose of GB2064 and had ≥1 evaluable post-dose pharmacokinetics sample.
Biomarker population: included all participants who received ≥1 dose of GB2064 and had ≥1 evaluable post-dose biomarker assessment.

Supplementary Figure 2

2a



2b



Note: Brown stain denotes LOXL2 presence.

H&E: hematoxylin and eosin staining; LOXL2: lysyl oxidase-2; MALDI: matrix-assisted laser desorption/ionization; MSI: mass spectrometry imaging; PK: pharmacokinetics; TE: target engagement

Supplementary Figure 3

3a



3b



ID: identification

Supplementary Figure 4



F: female; ID: identification; M: male